زوال عقل (Persian Wikipedia)

Analysis of information sources in references of the Wikipedia article "زوال عقل" in Persian language version.

refsWebsite

Global rank Persian rank

11nih.gov

4^th place

5^th place

7doi.org

2^nd place

5irna.ir

643^rd place

13^th place

2books.google.com

3^rd place

6^th place

1mayoclinic.org

1,610^th place

471^st place

1nice.org.uk

3,258^th place

1,207^th place

1web.archive.org

1^st place

1apll.ir

1,095^th place

21^st place

1iums.ac.ir

low place

555^th place

1bbc.com

20^th place

3^rd place

apll.ir

«زوال عقل» [پزشکی] هم‌ارزِ «dementia»؛ منبع: گروه واژه‌گزینی. جواد میرشکاری، ویراستار. دفتر اول. فرهنگ واژه‌های مصوب فرهنگستان. تهران: انتشارات فرهنگستان زبان و ادب فارسی. شابک ۹۶۴-۷۵۳۱-۳۱-۱ (ذیل سرواژهٔ زوال عقل)

bbc.com

«چه ورزش‌هایی بهتر می‌توانند از کاهش قوای مغزی و زوال عقل در دوران سالمندی پیشگیری کنند؟». BBC News فارسی. دریافت‌شده در ۲۰۲۲-۰۸-۲۴.

books.google.com

Hales RE (2008). The American Psychiatric Publishing Textbook of Psychiatry. American Psychiatric Pub. p. 311. ISBN 978-1-58562-257-3. Archived from the original on 2017-09-08.
Budson, Andrew; Solomon, Paul (2011). Memory loss: a practical guide for clinicians. [Edinburgh?]: Elsevier Saunders. ISBN 978-1-4160-3597-8.

doi.org

Nichols E, Szoeke CE, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. (GBD 2016 Dementia Collaborators) (January 2019). "Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016". The Lancet. Neurology. 18 (1): 88–106. doi:10.1016/S1474-4422(18)30403-4. PMC 6291454. PMID 30497964.
Rafii MS, Aisen PS (February 2009). "Recent developments in Alzheimer's disease therapeutics". BMC Medicine. 7: 7. doi:10.1186/1741-7015-7-7. PMC 2649159. PMID 19228370.
Lleó A, Greenberg SM, Growdon JH (2006). "Current pharmacotherapy for Alzheimer's disease". Annual Review of Medicine. 57 (1): 513–33. doi:10.1146/annurev.med.57.121304.131442. PMID 16409164.
Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C (2012). "The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model". Health Technology Assessment. 16 (21): 1–470. doi:10.3310/hta16210. PMC 4780923. PMID 22541366.
Lleó A, Greenberg SM, Growdon JH (2006). "Current pharmacotherapy for Alzheimer's disease". Annual Review of Medicine. 57 (1): 513–33. doi:10.1146/annurev.med.57.121304.131442. PMID 16409164.
Rodda J, Morgan S, Walker Z (October 2009). "Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine". International Psychogeriatrics. 21 (5): 813–24. doi:10.1017/S1041610209990354. PMID 19538824.
Birks J (January 2006). Birks JS (ed.). "Cholinesterase inhibitors for Alzheimer's disease". The Cochrane Database of Systematic Reviews (1): CD005593. doi:10.1002/14651858.CD005593. PMID 16437532.

irna.ir

https://www.irna.ir/news/82145460/خردسودگی-سفر-به-دیار-فراموشی
«شمار بیماران مبتلا به زوال عقل در جهان تا ۲۰۵۰ سه برابر می‌شود». ایرنا. ۲۰۱۵-۰۸-۳۰. دریافت‌شده در ۲۰۲۲-۰۸-۲۴.
«یک‌سوم کودکان انگلیسی در معرض ابتلا به بیماری زوال عقل قرار دارند». ایرنا. ۲۰۱۵-۰۹-۲۱. دریافت‌شده در ۲۰۲۲-۰۸-۲۴.
«نور خورشید، مؤثر در رفع اختلال خواب مبتلایان به زوال عقل». ایرنا. ۲۰۱۵-۱۰-۱۸. دریافت‌شده در ۲۰۲۲-۰۸-۲۴.
«اضطراب چگونه احتمال ابتلا به زوال عقل را افزایش می‌دهد». ایرنا. ۲۰۱۶-۰۱-۲۴. دریافت‌شده در ۲۰۲۲-۰۸-۲۴.

iums.ac.ir

ijpcp.iums.ac.ir

صادقی, مجید; کاظمی, حمیدرضا (2004-05-10). "شیوع دمانس و افسردگی در سالمندان ساکن در خانه‌های سالمندان استان تهران". مجله روان‌پزشکی و روان‌شناسی بالینی ایران. 9 (4): 49–55.

mayoclinic.org

"Dementia". mayoclinic.org. Mayo Clinic. Retrieved June 5, 2022.

nice.org.uk

cks.nice.org.uk

"Differential diagnosis dementia". NICE. Retrieved 20 January 2022.

nih.gov

pubmed.ncbi.nlm.nih.gov

Nichols E, Szoeke CE, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. (GBD 2016 Dementia Collaborators) (January 2019). "Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016". The Lancet. Neurology. 18 (1): 88–106. doi:10.1016/S1474-4422(18)30403-4. PMC 6291454. PMID 30497964.
Rafii MS, Aisen PS (February 2009). "Recent developments in Alzheimer's disease therapeutics". BMC Medicine. 7: 7. doi:10.1186/1741-7015-7-7. PMC 2649159. PMID 19228370.
Lleó A, Greenberg SM, Growdon JH (2006). "Current pharmacotherapy for Alzheimer's disease". Annual Review of Medicine. 57 (1): 513–33. doi:10.1146/annurev.med.57.121304.131442. PMID 16409164.
Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C (2012). "The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model". Health Technology Assessment. 16 (21): 1–470. doi:10.3310/hta16210. PMC 4780923. PMID 22541366.
Lleó A, Greenberg SM, Growdon JH (2006). "Current pharmacotherapy for Alzheimer's disease". Annual Review of Medicine. 57 (1): 513–33. doi:10.1146/annurev.med.57.121304.131442. PMID 16409164.
Rodda J, Morgan S, Walker Z (October 2009). "Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine". International Psychogeriatrics. 21 (5): 813–24. doi:10.1017/S1041610209990354. PMID 19538824.
Commission de la transparence (June 2012). "Drugs for Alzheimer's disease: best avoided. No therapeutic advantage" [Drugs for Alzheimer's disease: best avoided. No therapeutic advantage]. Prescrire International. 21 (128): 150. PMID 22822592.
Birks J (January 2006). Birks JS (ed.). "Cholinesterase inhibitors for Alzheimer's disease". The Cochrane Database of Systematic Reviews (1): CD005593. doi:10.1002/14651858.CD005593. PMID 16437532.

ncbi.nlm.nih.gov

Nichols E, Szoeke CE, Vollset SE, Abbasi N, Abd-Allah F, Abdela J, et al. (GBD 2016 Dementia Collaborators) (January 2019). "Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016". The Lancet. Neurology. 18 (1): 88–106. doi:10.1016/S1474-4422(18)30403-4. PMC 6291454. PMID 30497964.
Rafii MS, Aisen PS (February 2009). "Recent developments in Alzheimer's disease therapeutics". BMC Medicine. 7: 7. doi:10.1186/1741-7015-7-7. PMC 2649159. PMID 19228370.
Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C (2012). "The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model". Health Technology Assessment. 16 (21): 1–470. doi:10.3310/hta16210. PMC 4780923. PMID 22541366.

web.archive.org

Hales RE (2008). The American Psychiatric Publishing Textbook of Psychiatry. American Psychiatric Pub. p. 311. ISBN 978-1-58562-257-3. Archived from the original on 2017-09-08.